Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Bitetti Teresa Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Teresa Marie Bitetti, President of its Oncology Business Unit, received an equity award of 43,886 American Depositary Shares (ADSs) in the form of restricted stock units (RSUs). Each RSU represents the right to receive one ADS if vesting conditions are met.
The RSUs vest in three equal annual installments beginning on July 1, 2027, which means the award is tied to continued service over several years. After this grant, Bitetti directly holds 302,022 ADSs, reflecting her ongoing long-term ownership stake aligned with shareholders.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President and CEO Julie Kim reported equity compensation awards rather than market purchases or sales. On July 1, 2026, she received 22,800 Ordinary Shares and an award of 50,434 restricted stock units (RSUs), each RSU representing one American Depositary Share.
The RSUs tied to American Depositary Shares vest in three equal annual installments beginning on July 1, 2027. Following this grant, her directly held American Depositary Shares increased to 480,579.
She also received three Tax Obligation Awards covering 7,743, 7,741, and 7,741 Ordinary Shares, each economically equivalent to one Ordinary Share. These awards vest and are payable in cash primarily to cover tax obligations, with vesting dates in 2027, 2028, and 2029.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President of R&D Andrew Stewart Plump reported a new equity award in the form of restricted stock units (RSUs). He received 125,390 RSUs, each representing a contingent right to receive one American Depositary Share, as a compensation grant at no purchase price.
The RSUs vest in three equal annual installments beginning on July 1, 2027, meaning the award will be delivered over three years if vesting conditions are met. After this grant, he directly holds 931,962 American Depositary Shares and indirectly holds 281,307 American Depositary Shares through a trust.
TAKEDA PHARMACEUTICAL CO LTD director files initial ownership report. Kimura Koichiro filed a Form 3 as a director of Takeda Pharmaceutical, which is an initial statement of beneficial ownership required when someone becomes an insider. This filing does not report any share purchases, sales, or other transactions.
Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard filed an initial Form 3 reporting his holdings in the company. The filing shows he directly owns 795 American Depositary Shares as of the reported date. This is a baseline disclosure of his beneficial ownership rather than a new buy or sell transaction.
TAKEDA PHARMACEUTICAL CO LTD filed an initial Form 3 reporting that Paulus Stoffels is a director of the company. The filing shows no reported transactions in the company’s securities and no derivative positions, serving purely as a baseline disclosure of his insider status.
Takeda Pharmaceutical Company Limited has filed an updated translation of its Articles of Incorporation, reflecting the latest amendment made on June 29, 2026. The document sets out the company’s purpose, governance structure, and capital framework, including authorization for 3,500,000,000 shares and a unit share size of 100 shares.
It defines the roles of the Board of Directors, Audit and Supervisory Committee, and Accounting Auditors, along with procedures for shareholder meetings, record dates for voting and dividends, and director terms. The Articles also confirm Takeda’s April 1 to March 31 business year and establish rules for dividends, proxy voting, and electronic provision of meeting materials.
Takeda Pharmaceutical Company Limited reports the voting results from its 150th Annual General Meeting of Shareholders held on June 24, 2026. Shareholders approved a year-end dividend of 100 JPY per common share and elected all nominated directors, including eight non–Audit and Supervisory Committee members and three committee members.
They also approved one substitute director and authorized up to 260 million JPY in bonuses for eligible directors. All proposals passed with large majorities, with most director elections receiving approval rates above 90% of voting rights exercised.
Takeda Pharmaceutical presents its 2026 Annual Integrated Report, highlighting FY2025 performance, pipeline progress and sustainability milestones. Core Revenue was 4,505.7 billion yen (about $28.3 billion), down modestly as the VYVANSE loss of exclusivity weighed on sales, while Growth and Launch Products generated 2,313.3 billion yen and over half of total revenue.
Core Operating Profit was 1,172.5 billion yen (about $7.4 billion), supported by an efficiency program delivering roughly 300 billion yen in annualized cost savings. Reported Operating Profit fell 98.2% due to a large provision for AMITIZA antitrust litigation, driving reported EPS to -97 yen, though Core EPS rose to 517 yen.
Management guides FY2026 to low-single-digit Core Revenue decline and a 5–8% Core Operating Profit decline at constant exchange rates as Takeda invests heavily in launches for oveporexton, rusfertide and, later, zasocitinib. The company targets Core Operating Profit margins in the low-to-mid 30s%, a net debt/EBITDA ratio of 2x over time and maintains its progressive dividend, raising it to 200 yen for FY2025 and planning 204 yen for FY2026.
Beyond finances, Takeda emphasizes R&D strength, including positive Phase 3 data for key assets and a late-stage oncology partnership with Innovent. It reports a 58% reduction in Scope 1 and 2 greenhouse gas emissions from a FY2016 baseline, a 10% Scope 3 reduction from FY2022, 2,104 new patients in affordability-based assistance programs and 99.6% on-time, in-full product deliveries, underscoring its focus on patients, people, planet and governance.
Takeda Pharmaceutical Company Limited announced that Julie Kim has been formally appointed Representative Director, President and Chief Executive Officer, completing an 18‑month CEO transition. Shareholders elected her as an internal director at the 150th Annual General Meeting, after which the Board appointed her as CEO.
Former President & CEO Christophe Weber retired from the company and the Board upon conclusion of the meeting. The company highlighted that it has three major product launches planned in the next 12 months and a pipeline of five additional late‑stage innovative assets. The Board now has 11 members, including eight external directors, and key committees are composed solely of external directors.